TETi76 is a synthetic molecule identified by scientists for potentially treating blood and bone marrow cancer. This new pharmacological strategy enables the selective targeting of leukaemia cells with a specific type of mutation called TET2 mutation- commonly found in myeloid leukemia. Myeloid leukemia affects the cells of bone marrow from which blood cells are derived. The molecule replicates the effects of a natural molecule called 2HG (2-hydroxyglutarate) and amplifies it. 2HG (2-hydroxyglutarate) is known for inhibiting the enzymatic functions of TET genes.